Related Experiment Video
Updated: Aug 4, 2026
06:09
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Biochemical and pathological characterization of Lrrk2
Benoit I Giasson1, Jason P Covy, Nancy M Bonini
1Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6084, USA. giassonb@mail.med.upenn.edu
Annals of Neurology
|January 27, 2006
Summary
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of Parkinson's disease (PD). This study investigated LRRK2's biological and pathological roles, finding it accumulates in specific brain cells of PD patients.
Area of Science:
- Neuroscience
- Genetics
- Pathology
Background:
- Leucine-rich repeat kinase 2 (LRRK2) mutations are the most frequent genetic cause of Parkinson's disease (PD).
- Understanding LRRK2's biological and pathological properties is crucial for PD research.
- The G2019S mutation is a common LRRK2 variant associated with PD.
Purpose of the Study:
- To explore the biological and pathological characteristics of LRRK2.
- To investigate the distribution and accumulation of LRRK2 in the brain, particularly in individuals with the G2019S mutation.
Main Methods:
- Genetic analysis of autopsied patients with the G2019S LRRK2 mutation.
- Immunohistochemical and biochemical analysis using an LRRK2-specific antibody.
Main Results:
- Identified three patients with the G2019S LRRK2 mutation; two had classic PD with Lewy bodies (one with concurrent Alzheimer's pathology).
- The third patient presented with parkinsonism and dystrophic neurites in the substantia nigra intensely stained for LRRK2, with unique LRRK2 accumulations.
- Biochemical analysis revealed LRRK2 as a soluble, approximately 250 kDa cytoplasmic protein expressed widely in the brain and other organs.
Conclusions:
- The exact mechanism of LRRK2-associated parkinsonism is still unclear.
- LRRK2 mutations may predispose specific neuronal populations to cellular damage and abnormal protein aggregation.
- Further research is needed to understand how LRRK2 mutations lead to selective neuronal vulnerability in Parkinson's disease.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...